A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

NCT01218516 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Adenocarcinoma of the Lung

Interventions

BIOLOGICAL: Farletuzumab
OTHER: Placebo
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Pemetrexed
DRUG: Cisplatin

Sponsor

Morphotek